Add to ORKGRole of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial
Drug coated stents have reduced the incidence of in-stent restenosis with coronary intervention. Whe...
OBJECTIVE:The role of oral immunosuppressive therapy (OIT) to prevent restenosis after percutaneous ...
Percutaneous transluminal coronary angioplasty (PTCA) has greatly benefited patients with occluded c...
Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary st...
ObjectivesThe purpose of this study was to assess the role of oral rapamycin in decreased restenosis...
ObjectivesThe aim of this study was to establish safety and feasibility of oral Rapamycin at two dos...
Background – The development of coronary stents has revolutionized the practice of interventional ca...
In response to physiological stimuli (eg, wound healing),normally quiescent smooth muscle cells (SMC...
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reducti...
Objective The excellent results obtained with sirolimus (rapamicin)-eluting stents for preventing re...
Alexandre AbizaidInstitute Dante Pazzanese of Cardiology, Sao Paulo, BrazilAbstract: The sirolimus-e...
textabstractObjective: To assess the effectiveness of routine sirolimus eluting stent (SES) implanta...
located on the World Wide Web at: The online version of this article, along with updated information...
Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplast...
The role of oral immunosuppressive therapy (OIT) to prevent restenosis after percutaneous coronary i...
Drug coated stents have reduced the incidence of in-stent restenosis with coronary intervention. Whe...
OBJECTIVE:The role of oral immunosuppressive therapy (OIT) to prevent restenosis after percutaneous ...
Percutaneous transluminal coronary angioplasty (PTCA) has greatly benefited patients with occluded c...
Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary st...
ObjectivesThe purpose of this study was to assess the role of oral rapamycin in decreased restenosis...
ObjectivesThe aim of this study was to establish safety and feasibility of oral Rapamycin at two dos...
Background – The development of coronary stents has revolutionized the practice of interventional ca...
In response to physiological stimuli (eg, wound healing),normally quiescent smooth muscle cells (SMC...
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reducti...
Objective The excellent results obtained with sirolimus (rapamicin)-eluting stents for preventing re...
Alexandre AbizaidInstitute Dante Pazzanese of Cardiology, Sao Paulo, BrazilAbstract: The sirolimus-e...
textabstractObjective: To assess the effectiveness of routine sirolimus eluting stent (SES) implanta...
located on the World Wide Web at: The online version of this article, along with updated information...
Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplast...
The role of oral immunosuppressive therapy (OIT) to prevent restenosis after percutaneous coronary i...
Drug coated stents have reduced the incidence of in-stent restenosis with coronary intervention. Whe...
OBJECTIVE:The role of oral immunosuppressive therapy (OIT) to prevent restenosis after percutaneous ...
Percutaneous transluminal coronary angioplasty (PTCA) has greatly benefited patients with occluded c...